Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Label Revisions Ordered for Pomalyst, MabCampath, and More
January 27, 2021
- Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
- Japan to Set Up Real-Time Tracking System for COVID-19 Vaccination: Kono
January 26, 2021
- Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
- MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
- Japan Preps for COVID-19 Vaccine Rollout for HCPs by Late February: Minister
January 25, 2021
- Japan Govt Starts COVID-19 Vaccine Website, Plans Air/Land Shipments by Logistics Firms for Pfizer Shots
January 25, 2021
- MHLW Publishes Members’ Names of DPO; Disclosure of Minutes Expected as Early as Summer
January 25, 2021
- LDP Medical Legislator Group Proposes Stockpiling of EpiPen at COVID-19 Vaccination Centers
January 25, 2021
- MHLW Plans 4-Week Follow-Up Study on Early COVID-19 Vaccine Recipients
January 21, 2021
- Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
January 21, 2021
- Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
- LDP to Set Up Project Team for COVID-19 Vaccine Rollout, Submits Roadmap to PM
January 20, 2021
- Kato Has High Hopes for Kono’s Knack for Inter-Ministry Coordination for Vaccinations
January 20, 2021
- AMED to Fund 17 Research Projects for Development of COVID-19 Treatments
January 20, 2021
- MHLW Eyes 1st Revision of Drug Industry Vision in 8 Years as Off-Year Re-Pricing Takes Shape: Official
January 19, 2021
- Kono Responsible for Logistics Part of COVID-19 Vaccine Rollout
January 19, 2021
- MHLW to Lift Contraindication for Combined Use of Revatio/Ancaron, but Advise “Caution”
January 19, 2021
- Kono Tapped to Oversee COVID-19 Vaccine Rollout
January 19, 2021
- PAFSC to Reexamine Seikagaku’s Osteoarthritis Med on Jan. 29, Bayer’s Larotrectinib Up for Review Too
January 18, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…